Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline [Yahoo! Finance]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Yahoo! Finance
Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and set a $60 price target. The positive stance comes amid expectations that the company will deliver topline results from its first in-vivo CAR T program for patients before the end of the year. Photo by Toon Lambrechts on Unsplash Initial preclinical data have already shown robust dose-dependent CAR-T expansion in non-human primates. The data have also demonstrated sustained peripheral B-cell elimination from day 8 to day 36. The data suggest that in vivo CAR-T cells exhibit properties similar to those of traditional CAR-T treatments. Amid the expected positive clinical trial results, Legend Biotech has also reiterated plans to achieve profitability in 2026. Profitability would come even as the company focuses on developing its pipeline, focusing on in vivo and allogeneic CAR-T therapies. Similarly, Cantor Fitzgerald has also reiterated its bullish stance on the stock. On December 17, the research firm reaffirmed an Over
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San FranciscoPR Newswire
- Legend Biotech: Carvykti Driving Growth Amid FDA Regulatory Tailwinds [Seeking Alpha]Seeking Alpha
- Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Legend Biotech (NASDAQ:LEGN) was given a new $21.00 price target on by analysts at Jefferies Financial Group Inc..MarketBeat
- Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.MarketBeat
LEGN
Sec Filings
- 1/23/26 - Form 6-K
- 1/21/26 - Form 6-K
- 1/14/26 - Form 6-K
- LEGN's page on the SEC website